Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
Oded Icht(Rabin Medical Center), Avi Leader(Tel Aviv University), Nir Peled(Tel Aviv University), Oded Jacobi(Rabin Medical Center), Itamar Averbuch(Rabin Medical Center), Yosef Landman(Rabin Medical Center), Tzippy Shochat(Rabin Medical Center), Shai Shimony(Tel Aviv University), Alona Zer(Technion – Israel Institute of Technology), Daniel Reinhorn(Rabin Medical Center), Raz Mutai(Rabin Medical Center), Naama Darzi(Rabin Medical Center), Pia Raanani(Tel Aviv University), Elizabeth Dudnik(Rabin Medical Center), Ofer Rotem(Rabin Medical Center), Galia Spectre(Tel Aviv University)
Cited by 61
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642